http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H11503404-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-21 |
| filingDate | 1995-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1999-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H11503404-A |
| titleOfInvention | Pharmaceutical composition containing triclosan or a derivative thereof and EDTA or EGTA |
| abstract | (57) [Summary]nA pharmaceutical composition in the form of an oral unit dosage form for treating gastrointestinal disorders associated with Helicobacter pylori, wherein each unit comprises 0.1 to 300 mg of triclosan or a derivative thereof, or 0.1 to 300 mg of triclosan or a derivative thereof. A predetermined amount of an ester of triclosan or a derivative thereof, a cation salt of an ester of triclosan or a derivative thereof or a cation salt of a triclosan or a derivative thereof, and 1 to 600 mg of EDTA or a salt thereof or 1 to 3600 mg of EGTA or a thereof. And the weight ratio of triclosan to EDTA or a salt thereof in each unit is in the range of 1: 2 to 1:60, or the weight ratio of triclosan to EGTA or a salt thereof in each unit is 1: 2. It is in the range of 10: 1: 500 To. |
| priorityDate | 1994-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 79.